Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN011
MIFTS: 70

Adenoid Cystic Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Immune diseases, Neuronal diseases, Oral diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenoid Cystic Carcinoma

About this section

MalaCards integrated aliases for Adenoid Cystic Carcinoma:

Name: Adenoid Cystic Carcinoma 12 12 74 52 6 15 17 71
Salivary Gland Adenoid Cystic Carcinoma 12 54 15
Cylindroma 12 52
Adenoid Cystic Carcinoma of Salivary Gland 71
Carcinoma, Adenoid Cystic 43
Eccrine Dermal Cylindroma 71
Carcinoma Adenoid Cystic 54
Adenoid Cystic Cancer 12
Adenocystic Carcinoma 52
Carcinoma, Cribriform 71
Cribriform Carcinoma 52

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Gastrointestinal diseases Oral diseases Neuronal diseases Skin diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080202 DOID:4866
MeSH 43 D003528
NCIt 49 C2970
SNOMED-CT 67 11671000
UMLS 71 C0010606 C0205643 C0279751 more
Sources

Summaries for Adenoid Cystic Carcinoma

About this section
NIH Rare Diseases : 52 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma , a type of cancer that begins in glandular tissues . It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Symptoms depend on the tumor 's location. Salivary gland tumors may cause painless masses in the mouth or face. Tumors of the lacrimal gland may cause a bulging eye or changes in vision. Those affecting the windpipe or voice box may cause respiratory symptoms or changes in speech, respectively. Advanced tumors may cause pain and/or nerve paralysis, as ACC often spreads along the nerves. It may also spread through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. The cause of ACC is currently unknown. It typically does not run in families. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy . Unfortunately, ACC is typically an aggressive form of cancer that has a poor long-term outlook.

MalaCards based summary : Adenoid Cystic Carcinoma, also known as salivary gland adenoid cystic carcinoma, is related to cervical adenoid cystic carcinoma and trachea adenoid cystic carcinoma, and has symptoms including pain An important gene associated with Adenoid Cystic Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Promethazine and Doxepin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells.

Wikipedia : 74 Adenoid cystic carcinoma is a rare type of cancer that can exist in many different body sites. This... more...

Sources

Related Diseases for Adenoid Cystic Carcinoma

About this section

Diseases related to Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 722)
# Related Disease Score Top Affiliating Genes
1 cervical adenoid cystic carcinoma 35.6 NFIB MYB KRT7 KIT
2 trachea adenoid cystic carcinoma 35.4 NFIB MYBL1 MYB
3 breast adenoid cystic carcinoma 35.3 TP53 NFIB MYBL1 ERBB2
4 lung adenoid cystic carcinoma 35.3 NFIB MYBL1 KRT7 KIT
5 cutaneous adenocystic carcinoma 33.4 NFIB MYBL1 KRT7
6 ceruminous adenocarcinoma 33.3 KRT7 KRT14 KIT
7 adenoma 32.6 TP53 PIK3CA KRT7 KRAS CCND1
8 pleomorphic adenoma 32.5 TP53 KRT7 KRT14 HRAS ERBB2
9 polymorphous low-grade adenocarcinoma 32.4 NFIB MYB KIT CCND1
10 adenocarcinoma 32.3 TP53 PTEN PIK3CA KRT7 KRAS KIT
11 mucoepidermoid carcinoma 32.0 TP53 SERPINA3 NOTCH1 KRT7 KRT14 ERBB2
12 squamous cell papilloma 31.9 TP53 KRT14 HRAS
13 salivary gland carcinoma 31.9 TP53 SERPINA3 NFIB KRT7 KIT ERBB2
14 thyroid tumor 31.9 TP53 PTEN PIK3CA KRAS HRAS
15 myoepithelial carcinoma 31.9 TP53 PIK3CA KRT7 KRT14 HRAS
16 thyroid carcinoma 31.9 PTEN PIK3CA HRAS AKT1
17 small cell carcinoma 31.8 TP53 PTEN KRT7 KRAS KIT
18 squamous cell carcinoma 31.8 TP53 PTEN PIK3CA NOTCH1 KRT7 KRT14
19 papilloma 31.8 TP53 PTEN KRT7 KRT14 KRAS CCND1
20 epithelial-myoepithelial carcinoma 31.8 TP53 PIK3CA KRT7 KRT14 HRAS AKT1
21 meningioma, familial 31.7 TP53 SERPINA3 PTEN PIK3CA IDH1 ERBB2
22 basal cell carcinoma 31.7 TP53 PTEN NOTCH1 KRT7 KRT14 KIT
23 nasopharyngeal carcinoma 31.7 TP53 PTEN PIK3CA NOTCH1 HRAS ERBB2
24 basaloid squamous cell carcinoma 31.7 TP53 KRT7 KRT14
25 pleomorphic adenoma carcinoma 31.7 TP53 NFIB ERBB2
26 oral squamous cell carcinoma 31.7 TP53 PTEN HRAS CCND1 AKT1
27 cribriform carcinoma 31.7 KRT7 KIT ERBB2
28 exanthem 31.7 KRAS KIT HRAS ERBB2 AKT1
29 breast cancer 31.7 TP53 SERPINA3 PTEN PIK3CA NOTCH1 KRT7
30 esophageal cancer 31.6 TP53 PTEN PIK3CA KRAS HRAS ERBB2
31 in situ carcinoma 31.6 TP53 SERPINA3 PTEN PIK3CA KRT14 HRAS
32 renal cell carcinoma, nonpapillary 31.6 TP53 PTEN PIK3CA KRT7 KIT HRAS
33 squamous cell carcinoma, head and neck 31.6 TP53 PTEN PIK3CA NOTCH1 KRT14 KRAS
34 ductal carcinoma in situ 31.5 TP53 PTEN PIK3CA KRT14 ERBB2 CCND1
35 breast fibroadenoma 31.5 TP53 SERPINA3 KRT14 ERBB2
36 cystic teratoma 31.5 TP53 PTEN KRT7 KRAS KIT
37 adenoid basal cell carcinoma 31.5 KRT7 KIT
38 microglandular adenosis 31.4 TP53 KIT ERBB2
39 rhabdomyosarcoma 31.4 TP53 PTEN KRAS KIT HRAS CCND1
40 leukemia 31.4 TP53 NOTCH1 KRAS KIT JAK3 HRAS
41 lung cancer susceptibility 3 31.4 TP53 SERPINA3 PTEN PIK3CA NOTCH1 KRT7
42 myeloid leukemia 31.4 TP53 KRAS KIT IDH1 HRAS AKT1
43 spiradenoma 31.4 TP53 KRT7 KRT14 CYLD
44 cervical adenocarcinoma 31.3 TP53 PTEN KRT7 KRAS ERBB2 AKT1
45 mature teratoma 31.3 TP53 KRT7 KRAS KIT ERBB2
46 carcinosarcoma 31.3 TP53 PTEN PIK3CA KRT7 KRAS KIT
47 acinar cell carcinoma 31.3 TP53 SERPINA3 KRT7
48 large cell carcinoma 31.3 KRT7 KRAS KIT HRAS ERBB2
49 hemangioma 31.3 TP53 PTEN NOTCH1 KRT7 KRAS KIT
50 neurofibroma 31.3 TP53 PTEN KIT

Graphical network of the top 20 diseases related to Adenoid Cystic Carcinoma:



Diseases related to Adenoid Cystic Carcinoma
Sources

Symptoms & Phenotypes for Adenoid Cystic Carcinoma

About this section

UMLS symptoms related to Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 60)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.63 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.63 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.63 KRAS
4 Decreased viability GR00106-A-0 10.63 KRAS
5 Decreased viability GR00221-A-1 10.63 AKT1 CYLD HRAS KRAS PIK3CA KIT
6 Decreased viability GR00221-A-2 10.63 AKT1 CYLD HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.63 AKT1 HRAS
8 Decreased viability GR00221-A-4 10.63 AKT1 PIK3CA
9 Decreased viability GR00249-S 10.63 AKT1 CYLD
10 Decreased viability GR00301-A 10.63 CYLD KRAS KIT
11 Decreased viability GR00381-A-1 10.63 KRAS
12 Decreased viability GR00402-S-2 10.63 CYLD PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-100 10.45 MYB
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.45 JAK3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 10.45 MYB
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 10.45 MYB
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-122 10.45 MYB
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-138 10.45 NOTCH1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.45 MYB
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-147 10.45 MYB
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-161 10.45 MYB
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.45 MYB
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 10.45 MYB
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.45 MYB
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-183 10.45 HRAS
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.45 MYB
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 10.45 JAK3
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.45 MYB
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-205 10.45 NOTCH1
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-214 10.45 NOTCH1
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.45 JAK3
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-43 10.45 HRAS JAK3
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-6 10.45 JAK3
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.45 MYB NOTCH1
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.45 HRAS
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.45 MYB NOTCH1
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 10.45 NOTCH1
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.45 JAK3
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-83 10.45 MYB
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.45 HRAS
41 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10 NFIB
42 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10 KRAS
43 Increased shRNA abundance (Z-score > 2) GR00366-A-134 10 CCND1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10 CCND1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10 BCOR NFIB
46 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10 CCND1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10 BCOR CCND1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10 CCND1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10 AKT1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10 KRAS

MGI Mouse Phenotypes related to Adenoid Cystic Carcinoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AKT1 BCOR CCND1 CYLD ERBB2 JAK3
2 growth/size/body region MP:0005378 10.48 AKT1 BCOR CCND1 CYLD ERBB2 HRAS
3 endocrine/exocrine gland MP:0005379 10.46 AKT1 CCND1 CYLD ERBB2 HRAS JAK3
4 homeostasis/metabolism MP:0005376 10.45 AKT1 CCND1 CYLD ERBB2 HRAS IDH1
5 cardiovascular system MP:0005385 10.41 AKT1 BCOR CCND1 ERBB2 HRAS JAK3
6 mortality/aging MP:0010768 10.41 AKT1 BCOR CCND1 CYLD ERBB2 HRAS
7 immune system MP:0005387 10.39 AKT1 BCOR CCND1 CYLD IDH1 JAK3
8 behavior/neurological MP:0005386 10.38 AKT1 CCND1 CYLD ERBB2 HRAS KIT
9 hematopoietic system MP:0005397 10.38 AKT1 BCOR CCND1 CYLD IDH1 JAK3
10 integument MP:0010771 10.37 AKT1 CCND1 CYLD ERBB2 HRAS KIT
11 digestive/alimentary MP:0005381 10.35 CCND1 CYLD ERBB2 HRAS JAK3 KIT
12 embryo MP:0005380 10.27 AKT1 BCOR ERBB2 KIT KRAS MYB
13 craniofacial MP:0005382 10.24 CCND1 ERBB2 HRAS KIT KRAS KRT14
14 neoplasm MP:0002006 10.21 AKT1 CCND1 CYLD ERBB2 HRAS KIT
15 nervous system MP:0003631 10.18 AKT1 BCOR CCND1 ERBB2 HRAS KIT
16 normal MP:0002873 10.15 AKT1 CCND1 CYLD ERBB2 HRAS KIT
17 muscle MP:0005369 10.06 AKT1 ERBB2 KIT KRAS NOTCH1 PIK3CA
18 reproductive system MP:0005389 10 AKT1 CCND1 ERBB2 KIT KRAS KRT14
19 respiratory system MP:0005388 9.97 AKT1 CCND1 CYLD ERBB2 HRAS IDH1
20 pigmentation MP:0001186 9.87 JAK3 KIT KRAS KRT14 NOTCH1 PTEN
21 skeleton MP:0005390 9.7 AKT1 CCND1 ERBB2 HRAS IDH1 KIT
22 vision/eye MP:0005391 9.32 CCND1 JAK3 KIT KRAS KRT14 NFIB
Sources

Drugs & Therapeutics for Adenoid Cystic Carcinoma

About this section

Drugs for Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Promethazine Approved, Investigational Phase 3 60-87-7 4927
2
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
3
Histamine Approved, Investigational Phase 3 51-45-6 774
4
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
7
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
8
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
9
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
10
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Porfiromycin Investigational Phase 3 801-52-5
13 Anti-Bacterial Agents Phase 3
14 Antibiotics, Antitubercular Phase 3
15 Neurotransmitter Agents Phase 3
16 Antidepressive Agents Phase 3
17 Hypnotics and Sedatives Phase 3
18 Histamine Antagonists Phase 3
19 Psychotropic Drugs Phase 3
20
Histamine Phosphate Phase 3 51-74-1 65513
21 Antidepressive Agents, Tricyclic Phase 3
22 Alkylating Agents Phase 3
23 Liver Extracts Phase 3
24 Anesthetics Phase 3
25 Narcotics Phase 3
26 Analgesics Phase 3
27 Analgesics, Opioid Phase 3
28 Anesthetics, General Phase 3
29 Anesthetics, Intravenous Phase 3
30 Mitomycins Phase 3
31 Muscarinic Agonists Phase 3
32 Cholinergic Agents Phase 3
33 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
34 Hormone Antagonists Phase 2, Phase 3
35 Antifungal Agents Phase 2, Phase 3
36 Central Nervous System Stimulants Phase 3
37 Contraceptives, Oral Phase 3
38 Antineoplastic Agents, Hormonal Phase 3
39 Contraceptive Agents Phase 3
40
Megestrol Phase 3 3562-63-8 19090 3080587
41
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
42
Indinavir Approved Phase 2 150378-17-9 5362440
43
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
44
Gemcitabine Approved Phase 2 95058-81-4 60750
45
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
46
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
50
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 RADIATION WITH MITOMYCIN C OR PORFIROMYCIN IN THE TREATMENT OF CANCER OF THE HEAD AND NECK AREA Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
4 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
5 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
7 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
8 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
9 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
10 Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety Unknown status NCT02883374 Phase 2 Chidamide
11 Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT Unknown status NCT00180921 Phase 2 Imatinib
12 Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study Unknown status NCT01192087 Phase 1, Phase 2 Cetuximab
13 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
15 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
16 Phase II Study of TKI258 (Dovitinib) Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01417143 Phase 2 TKI258 (Dovitinib):
17 A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) Completed NCT01678105 Phase 2 Dovitinib
18 Phase II Study of RAD001monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma Completed NCT01152840 Phase 2 RAD001
19 Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Head and Neck Adenoid Cystic Carcinoma Completed NCT00581360 Phase 2 doxorubicin and bortezomib
20 A Phase II Study of Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01558661 Phase 2 AG-013736 (AXITINIB)
21 A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
22 A Phase 2 Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands Completed NCT00886132 Phase 2 Sunitinib
23 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Subjects With Locally Advanced, Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Completed NCT01175980 Phase 2 Vorinostat
24 Phase II Trial of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck Completed NCT00077428 Phase 2 bortezomib;doxorubicin hydrochloride
25 A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Completed NCT01524692 Phase 2 Dovitinib (TKI258)
26 Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors Completed NCT00859937 Phase 2 Dasatinib
27 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
28 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
29 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
30 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
31 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
32 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
33 Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract Completed NCT02860936 Phase 2 Lenvatinib
34 A Phase II Trial of the HIV Protease Inhibitor Nelfinavir in Patients With Recurrent Symptomatic Adenoid Cystic Cancers of the Head and Neck Completed NCT01065844 Phase 2 Nelfinavir
35 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
36 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
37 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
38 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Completed NCT02393820 Phase 2 pazopanib
39 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
40 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
41 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
42 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
43 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
44 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
45 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
46 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
47 Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung Completed NCT00021333 Phase 2 cisplatin;paclitaxel
48 Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract Completed NCT02857712 Phase 2 Axitinib
49 Chidamide Combined With Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma: A Prospective, Open-label, Phase II Study of a Single Center Recruiting NCT03639168 Phase 2 Chidamide combined with cisplatin
50 A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Recruiting NCT04209660 Phase 2 Lenvatinib;Pembrolizumab

Search NIH Clinical Center for Adenoid Cystic Carcinoma

Cochrane evidence based reviews: carcinoma, adenoid cystic

Sources

Genetic Tests for Adenoid Cystic Carcinoma

About this section
Sources

Anatomical Context for Adenoid Cystic Carcinoma

About this section

MalaCards organs/tissues related to Adenoid Cystic Carcinoma:

40
Salivary Gland, Breast, Lung, Trachea, Cervix, Lymph Node, Brain
Sources

Publications for Adenoid Cystic Carcinoma

About this section

Articles related to Adenoid Cystic Carcinoma:

(show top 50) (show all 4539)
# Title Authors PMID Year
1
Genetic Characterization of Adenoid Cystic Carcinoma of the Minor Salivary Glands: A Potential Familial Occurrence in First-Degree Relatives. 52 61
28210977 2017
2
C-kit gene mutations in adenoid cystic carcinoma are rare. 54 61
20514080 2010
3
Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma. 61 54
20219417 2010
4
Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. 54 61
19877114 2010
5
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). 61 54
19574086 2009
6
Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 61 54
19659475 2009
7
Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. 61 54
19617878 2009
8
Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. 54 61
18983466 2008
9
Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. 61 54
17936671 2008
10
[Effects of basic fibroblast growth factor on the proliferation of human salivary adenoid cystic carcinoma cell line ACC-2 and extracellular signal-regulated kinase, Cyclin D1, p2waf/cip1 signaling pathway]. 54 61
18605443 2008
11
Effect of exogenous bFGF on the proliferation of human adenoid cystic carcinoma ACC-2 cells. 61 54
18481005 2008
12
Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. 61 54
18084258 2008
13
[Prognostic value of immunohistochemistry in salivary gland cancer]. 54 61
18214402 2008
14
Expression of neural cell adhesion molecule in salivary adenoid cystic carcinoma and its correlation with perineural invasion. 54 61
17982624 2007
15
Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. 54 61
17932891 2007
16
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. 61 54
17761983 2007
17
[Expression and significance of E-cadherin in adenoid cystic carcinoma of the salivary glands]. 61 54
17927866 2007
18
Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. 61 54
16996782 2007
19
Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. 54 61
17391298 2007
20
[Effect of mechanical stimulation on the expression of E-cadherin/cateninin complex in salivary adenoid cystic carcinoma]. 54 61
17375572 2007
21
A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. 61 54
16757202 2007
22
Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. 61 54
16807072 2007
23
Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. 54 61
16996786 2006
24
Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. 61 54
16810311 2006
25
[Expression of Pin1, beta-catenin and cyclin D1 in salivary adenoid cystic carcinoma and its significance]. 61 54
17129455 2006
26
Aberrant expression of beta-catenin, Pin1 and cylin D1 in salivary adenoid cystic carcinoma: relation to tumor proliferation and metastasis. 61 54
16865250 2006
27
Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. 61 54
16636670 2006
28
Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. 54 61
16094606 2006
29
Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. 61 54
16184379 2006
30
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 61 54
16140564 2006
31
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. 61 54
16258515 2005
32
Clinical prognostic factors in malignant parotid gland tumors. 61 54
16274796 2005
33
Induction of apoptosis in human salivary gland tumor cells by anti-NCAM antibody. 54 61
16211277 2005
34
Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. 61 54
15846389 2005
35
Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. 61 54
16243805 2005
36
Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. 54 61
16054424 2005
37
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. 54 61
16135502 2005
38
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 54 61
16082245 2005
39
Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. 61 54
15959912 2005
40
Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. 54 61
15899777 2005
41
[Expression and significance of cyclin D1 in human adenoid cystic carcinoma]. 54 61
16078452 2005
42
Adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of minor salivary glands: a comparative immunohistochemical study using the epithelial membrane and carcinoembryonic antibodies. 61 54
15888109 2005
43
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. 61 54
15863127 2005
44
Expression of IgSF in salivary adenoid cystic carcinoma and its relationship with invasion and metastasis. 54 61
15817073 2005
45
Expression of beta-catenin, E-cadherin and cyclin D1 in adenoid cystic carcinoma of the salivary gland. 54 61
15943036 2005
46
P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. 54 61
15792122 2005
47
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. 61 54
15659505 2005
48
"Parapharyngeal space" tumors: a cytopathological study of 24 cases on fine-needle aspiration. 54 61
15584054 2005
49
Lip cancer experience in Mexico. An 11-year retrospective study. 54 61
15509490 2004
50
Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland. 61 54
14714130 2004
Sources

Variations for Adenoid Cystic Carcinoma

About this section

ClinVar genetic disease variations for Adenoid Cystic Carcinoma:

6 (show top 50) (show all 59) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYBL1 , NFIB t(8;9)(q13.1;p22.3)Translocation Pathogenic 495136 8:67501293-67501294
2 MYB , NFIB t(6;9)(q23.3;p22.3)Translocation Pathogenic 495137 6:135522688-135522689
3 MYB , NFIB t(6;9)(q23.3;p22.3)Translocation Pathogenic 495138 6:135515857-135515858
4 MYB , NFIB t(6;9)(q23.3;p22.3)Translocation Pathogenic 495139 6:135516358-135516359
5 MYB , NFIB t(6;9)(q23.3;p22.3)Translocation Pathogenic 495140 6:135516423-135516424
6 KRAS NM_033360.4(KRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
7 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
8 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
9 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
10 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg)SNV Pathogenic 31945 rs121913272 3:178927980-178927980 3:179210192-179210192
11 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
12 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
13 JAK3 NM_000215.3(JAK3):c.1765G>A (p.Gly589Ser)SNV Pathogenic 265205 rs886039394 19:17947959-17947959 19:17837150-17837150
14 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys)SNV Pathogenic 376050 rs121913284 3:178921553-178921553 3:179203765-179203765
15 IDH1 NM_001282386.1(IDH1):c.395G>T (p.Arg132Leu)SNV Pathogenic/Likely pathogenic 375889 rs121913500 2:209113112-209113112 2:208248388-208248388
16 IDH1 NM_001282386.1(IDH1):c.394C>G (p.Arg132Gly)SNV Pathogenic/Likely pathogenic 375892 rs121913499 2:209113113-209113113 2:208248389-208248389
17 IDH1 NM_001282386.1(IDH1):c.394C>A (p.Arg132Ser)SNV Pathogenic/Likely pathogenic 375893 rs121913499 2:209113113-209113113 2:208248389-208248389
18 PIK3CA NM_006218.4(PIK3CA):c.3129G>A (p.Met1043Ile)SNV Pathogenic/Likely pathogenic 179173 rs121913283 3:178952074-178952074 3:179234286-179234286
19 TP53 NM_001126112.2(TP53):c.638G>C (p.Arg213Pro)SNV Pathogenic/Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
20 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser)SNV Pathogenic/Likely pathogenic 12370 rs28934874 17:7578479-7578479 17:7675161-7675161
21 TP53 NM_001126112.2(TP53):c.638G>T (p.Arg213Leu)SNV Likely pathogenic 376650 rs587778720 17:7578211-7578211 17:7674893-7674893
22 TP53 NM_001126112.2(TP53):c.637C>G (p.Arg213Gly)SNV Likely pathogenic 376651 rs397516436 17:7578212-7578212 17:7674894-7674894
23 PIK3CA NM_006218.4(PIK3CA):c.1258T>G (p.Cys420Gly)SNV Likely pathogenic 376469 rs121913272 3:178927980-178927980 3:179210192-179210192
24 PIK3CA NM_006218.4(PIK3CA):c.3127A>G (p.Met1043Val)SNV Likely pathogenic 376485 rs1057519936 3:178952072-178952072 3:179234284-179234284
25 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr)SNV Likely pathogenic 376486 rs1057519937 3:178952073-178952073 3:179234285-179234285
26 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu)SNV Likely pathogenic 376487 rs1057519936 3:178952072-178952072 3:179234284-179234284
27 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile)SNV Likely pathogenic 376488 rs1057519938 3:178921552-178921552 3:179203764-179203764
28 PIK3CA NM_006218.4(PIK3CA):c.1034A>C (p.Asn345Thr)SNV Likely pathogenic 376489 rs1057519938 3:178921552-178921552 3:179203764-179203764
29 PIK3CA NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His)SNV Likely pathogenic 376490 rs1057519939 3:178921551-178921551 3:179203763-179203763
30 SF3B1 NM_012433.3(SF3B1):c.1874G>A (p.Arg625His)SNV Likely pathogenic 376534 rs1057519961 2:198267483-198267483 2:197402759-197402759
31 SF3B1 NM_012433.3(SF3B1):c.1873C>T (p.Arg625Cys)SNV Likely pathogenic 376535 rs775623976 2:198267484-198267484 2:197402760-197402760
32 SF3B1 NM_012433.3(SF3B1):c.1873C>G (p.Arg625Gly)SNV Likely pathogenic 376536 rs775623976 2:198267484-198267484 2:197402760-197402760
33 IDH1 NM_001282386.1(IDH1):c.394C>T (p.Arg132Cys)SNV Likely pathogenic 375891 rs121913499 2:209113113-209113113 2:208248389-208248389
34 CREBBP NM_004380.3(CREBBP):c.4337G>T (p.Arg1446Leu)SNV Likely pathogenic 376386 rs1057519884 16:3788617-3788617 16:3738616-3738616
35 CREBBP NM_004380.3(CREBBP):c.4337G>A (p.Arg1446His)SNV Likely pathogenic 376387 rs1057519884 16:3788617-3788617 16:3738616-3738616
36 CREBBP NM_004380.3(CREBBP):c.4336C>G (p.Arg1446Gly)SNV Likely pathogenic 376388 rs398124146 16:3788618-3788618 16:3738617-3738617
37 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys)SNV Likely pathogenic 376414 rs867384286 4:153249385-153249385 4:152328233-152328233
38 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His)SNV Likely pathogenic 376415 rs1057519895 4:153249384-153249384 4:152328232-152328232
39 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro)SNV Likely pathogenic 376416 rs1057519895 4:153249384-153249384 4:152328232-152328232
40 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu)SNV Likely pathogenic 376417 rs1057519895 4:153249384-153249384 4:152328232-152328232
41 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly)SNV Likely pathogenic 376418 rs867384286 4:153249385-153249385 4:152328233-152328233
42 TP53 NM_001126112.2(TP53):c.451C>A (p.Pro151Thr)SNV Likely pathogenic 12369 rs28934874 17:7578479-7578479 17:7675161-7675161
43 NOTCH1 NM_017617.5(NOTCH1):c.4045_4052del (p.Ala1349fs)deletion Likely pathogenic 495129 rs1554728034 9:139400296-139400303 9:136505844-136505851
44 NOTCH1 NM_017617.5(NOTCH1):c.2825G>A (p.Cys942Tyr)SNV Likely pathogenic 495128 rs1554728658 9:139404329-139404329 9:136509877-136509877
45 ARID2 NM_152641.4(ARID2):c.2989C>T (p.Gln997Ter)SNV Likely pathogenic 495130 rs1555155110 12:46244895-46244895 12:45851112-45851112
46 BCOR NM_001123385.2(BCOR):c.4787_4802del (p.Gly1596fs)deletion Likely pathogenic 495132 rs1555913337 X:39913526-39913541 X:40054273-40054288
47 BCOR NM_001123385.2(BCOR):c.4063G>T (p.Glu1355Ter)SNV Likely pathogenic 495127 rs780712297 X:39922109-39922109 X:40062856-40062856
48 BCOR NM_001123385.2(BCOR):c.398_399insAC (p.Ala134fs)insertion Likely pathogenic 495125 rs1555919960 X:39934200-39934201 X:40074947-40074948
49 CREBBP NM_004380.3(CREBBP):c.4336C>T (p.Arg1446Cys)SNV Conflicting interpretations of pathogenicity 95047 rs398124146 16:3788618-3788618 16:3738617-3738617
50 FGFR2 NM_000141.5(FGFR2):c.1144T>C (p.Cys382Arg)SNV Conflicting interpretations of pathogenicity 376431 rs121913474 10:123274774-123274774 10:121515260-121515260

Cosmic variations for Adenoid Cystic Carcinoma:

9 (show top 50) (show all 37549)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143041461 WASF2 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.15G>T p.T5= 1:27428876-27428876 16
2 COSM87028709 TSC2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2402C>T p.A801V 16:2074246-2074246 16
3 COSM85719495 TSC1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2684T>A p.V895D 9:132897552-132897552 16
4 COSM84855029 TRPV5 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.554A>G p.H185R 7:142929054-142929054 16
5 COSM99625361 TP53BP1 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.3869C>G p.T1290S 15:43422086-43422086 16
6 COSM87905712 TP53 salivary gland,minor,carcinoma,adenocarcinoma c.775G>T p.D259Y 17:7674188-7674188 16
7 COSM88420642 THRA salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.1162C>T p.R388W 17:40093071-40093071 16
8 COSM96852092 TENT5C salivary gland,minor,carcinoma,adenoid cystic carcinoma c.833T>A p.F278Y 1:117623701-117623701 16
9 COSM86749613 STAG2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2405T>G p.I802S 23:124071195-124071195 16
10 COSM88093366 SOX9 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1457T>A p.V486D 17:72124314-72124314 16
11 COSM84674496 SMO salivary gland,major,carcinoma,adenoid cystic carcinoma c.385G>C p.V129L 7:129203437-129203437 16
12 COSM89651491 SMARCA4 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2372C>T p.A791V 19:11013046-11013046 16
13 COSM87293136 SLC26A2 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.1474C>T p.R492W 5:149981067-149981067 16
14 COSM89628192 SF3B1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.3254C>T p.A1085V 2:197397997-197397997 16
15 COSM103044749 SETD2 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.6379C>T p.Q2127* 3:47057405-47057405 16
16 COSM87217226 RUNX1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.958C>T p.R320* 21:34799310-34799310 16
17 COSM88241411 RPTOR salivary gland,minor,carcinoma,adenoid cystic carcinoma c.734C>T p.A245V 17:80754089-80754089 16
18 COSM85226318 RNF38 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.623A>G p.H208R 9:36357890-36357890 16
19 COSM97325050 RIT1 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.286C>G p.Q96E 1:155904733-155904733 16
20 COSM86632369 RB1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.1817A>G p.Y606C 13:48456206-48456206 16
21 COSM86190586 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.3026T>G p.L1009R 5:87389493-87389493 16
22 COSM86201304 RASA1 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2603+2T>A p.? 5:87379852-87379852 16
23 COSM86829907 RARA salivary gland,minor,carcinoma,adenoid cystic carcinoma c.691C>G p.L231V 17:40352391-40352391 16
24 COSM101805989 PTPRD salivary gland,major,carcinoma,adenoid cystic carcinoma c.3542G>A p.R1181H 9:8465638-8465638 16
25 COSM146439398 PTPN11 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1517C>T p.S506L 12:112489081-112489081 16
26 COSM96870842 PTEN salivary gland,major,carcinoma,adenoid cystic carcinoma c.764T>C p.V255A 10:87957982-87957982 16
27 COSM91776528 PPP2R1A salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.548G>A p.R183Q 19:52212730-52212730 16
28 COSM91776436 PPP2R1A salivary gland,major,carcinoma,adenoid cystic carcinoma c.547C>T p.R183W 19:52212729-52212729 16
29 COSM96441053 PIK3CG salivary gland,minor,carcinoma,adenoid cystic carcinoma c.2951C>A p.P984Q 7:106886213-106886213 16
30 COSM87132245 PIK3CA salivary gland,major,carcinoma,adenoid cystic carcinoma c.3140A>G p.H1047R 3:179234297-179234297 16
31 COSM132937325 PIK3C2G salivary gland,major,carcinoma,adenoid cystic carcinoma c.1975C>G p.P659A 12:18381860-18381860 16
32 COSM89707157 PGR salivary gland,major,carcinoma,adenoid cystic carcinoma c.1604C>G p.P535R 11:101127467-101127467 16
33 COSM87509250 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2158A>T p.T720S 9:84955503-84955503 16
34 COSM87509240 NTRK2 salivary gland,major,carcinoma,adenoid cystic carcinoma c.2336T>C p.I779T 9:85021256-85021256 16
35 COSM84166347 NR1D1 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.*12G>A p.? 17:40093071-40093071 16
36 COSM87686111 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.403+1G>C p.? 9:136523716-136523716 16
37 COSM87645161 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.7400C>A p.S2467* 9:136496339-136496339 16
38 COSM87655472 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.1367G>A p.C456Y 9:136517826-136517826 16
39 COSM87673614 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.973A>G p.N325D 9:136518717-136518717 16
40 COSM87642161 NOTCH1 salivary gland,minor,carcinoma,adenoid cystic carcinoma c.5101G>C p.A1701P 9:136503248-136503248 16
41 COSM89198195 MYCN salivary gland,major,carcinoma,adenoid cystic carcinoma c.1336A>G p.K446E 2:15946038-15946038 16
42 COSM91444409 MITF salivary gland,major,carcinoma,adenoid cystic carcinoma c.193C>T p.R65C 3:69879222-69879222 16
43 COSM88845277 MET salivary gland,major,carcinoma,adenoid cystic carcinoma c.1249C>G p.R417G 7:116731716-116731716 16
44 COSM85374504 MELK salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.817T>C p.W273R 9:36633183-36633183 16
45 COSM95014362 MAX salivary gland,minor,carcinoma,adenoid cystic carcinoma c.295+1G>A p.? 14:65077912-65077912 16
46 COSM96060242 MAP2 salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.31G>T p.A11S 2:209653201-209653201 16
47 COSM88018921 KRAS salivary gland,mouth roof,carcinoma,adenoid cystic carcinoma c.50G>A p.S17N 12:25245335-25245335 16
48 COSM87721482 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.10118C>A p.S3373* 12:49037238-49037238 16
49 COSM87714732 KMT2D salivary gland,major,carcinoma,adenoid cystic carcinoma c.4406G>A p.W1469* 12:49046621-49046621 16
50 COSM87672885 KMT2D salivary gland,minor,carcinoma,adenoid cystic carcinoma c.13450C>T p.R4484* 12:49031255-49031255 16

Copy number variations for Adenoid Cystic Carcinoma from CNVD:

7 (show top 50) (show all 209)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13805 1 1 61300000 Deletion Adenoid cystic carcinoma
2 31809 1 31200000 32688000 Loss BAI2 Adenoid cystic carcinoma
3 31810 1 31200000 32688000 Loss EIF3S2 Adenoid cystic carcinoma
4 31811 1 31200000 32688000 Loss FABP3 Adenoid cystic carcinoma
5 31812 1 31200000 32688000 Loss HDAC1 Adenoid cystic carcinoma
6 31813 1 31200000 32688000 Loss IQCC Adenoid cystic carcinoma
7 31814 1 31200000 32688000 Loss KHDRBS1 Adenoid cystic carcinoma
8 31815 1 31200000 32688000 Loss LCK Adenoid cystic carcinoma
9 31816 1 31200000 32688000 Loss MARCKSL1 Adenoid cystic carcinoma
10 31817 1 31200000 32688000 Loss PTP4A2 Adenoid cystic carcinoma
11 31818 1 31200000 32688000 Loss PUM1 Adenoid cystic carcinoma
12 31819 1 31200000 32688000 Loss RBBP4 Adenoid cystic carcinoma
13 31820 1 31200000 32688000 Loss SERINC2 Adenoid cystic carcinoma
14 31821 1 31200000 32688000 Loss TXLNA Adenoid cystic carcinoma
15 33928 1 50618000 52179000 Loss CDKN2C Adenoid cystic carcinoma
16 33929 1 50618000 52179000 Loss EPS15 Adenoid cystic carcinoma
17 33930 1 50618000 52179000 Loss FAF1 Adenoid cystic carcinoma
18 33931 1 50618000 52179000 Loss NRD1 Adenoid cystic carcinoma
19 33932 1 50618000 52179000 Loss RAB3B Adenoid cystic carcinoma
20 33933 1 50618000 52179000 Loss RNF11 Adenoid cystic carcinoma
21 50143 11 114500000 121200000 Deletion Adenoid cystic carcinoma
22 50146 11 114500000 121200000 Gain Salivary gland adenoid cystic carcinoma
23 58545 11 68400000 70400000 Deletion Adenoid cystic carcinoma
24 58546 11 68400000 70400000 Gain Salivary gland adenoid cystic carcinoma
25 61970 12 103800000 109000000 LOH Adenoid cystic carcinoma
26 64283 12 125900000 133851895 LOH Adenoid cystic carcinoma
27 67068 12 35800000 133851895 Loss Adenoid cystic carcinoma
28 67236 12 38200000 58100000 Deletion Adenoid cystic carcinoma
29 67639 12 43743000 50676000 Loss ACVR1B Adenoid cystic carcinoma
30 67640 12 43743000 50676000 Loss ACVRL1 Adenoid cystic carcinoma
31 67641 12 43743000 50676000 Loss ADCY6 Adenoid cystic carcinoma
32 67642 12 43743000 50676000 Loss AMIGO2 Adenoid cystic carcinoma
33 67643 12 43743000 50676000 Loss ANP32D Adenoid cystic carcinoma
34 67644 12 43743000 50676000 Loss ARF3 Adenoid cystic carcinoma
35 67645 12 43743000 50676000 Loss ATF1 Adenoid cystic carcinoma
36 67646 12 43743000 50676000 Loss CCNT1 Adenoid cystic carcinoma
37 67647 12 43743000 50676000 Loss COL2A1 Adenoid cystic carcinoma
38 67648 12 43743000 50676000 Loss DDX23 Adenoid cystic carcinoma
39 67649 12 43743000 50676000 Loss FAIM2 Adenoid cystic carcinoma
40 67650 12 43743000 50676000 Loss HDAC7A Adenoid cystic carcinoma
41 67651 12 43743000 50676000 Loss LALBA Adenoid cystic carcinoma
42 67652 12 43743000 50676000 Loss LETMD1 Adenoid cystic carcinoma
43 67653 12 43743000 50676000 Loss LIMA1 Adenoid cystic carcinoma
44 67654 12 43743000 50676000 Loss MLL2 Adenoid cystic carcinoma
45 67655 12 43743000 50676000 Loss PFKM Adenoid cystic carcinoma
46 67656 12 43743000 50676000 Loss PLEKHA9 Adenoid cystic carcinoma
47 67657 12 43743000 50676000 Loss PRKAG1 Adenoid cystic carcinoma
48 67658 12 43743000 50676000 Loss RACGAP1 Adenoid cystic carcinoma
49 67659 12 43743000 50676000 Loss RAPGEF3 Adenoid cystic carcinoma
50 67660 12 43743000 50676000 Loss RHEBL1 Adenoid cystic carcinoma
Sources

Expression for Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Adenoid Cystic Carcinoma.
Sources

Pathways for Adenoid Cystic Carcinoma

About this section

Pathways related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.15 TP53 SERPINA3 PTEN PIK3CA KRAS KIT
2
ERK Signaling 63
Show member pathways
 13.94 TP53 PTEN NOTCH1 KRAS KIT JAK3
3
GPCR Pathway 63
Show member pathways
 13.81 TP53 NOTCH1 KRAS KIT JAK3 HRAS
4
TGF-Beta Pathway 63
Show member pathways
 13.64 TP53 PIK3CA KRAS KIT JAK3 HRAS
5
Developmental Biology 65
Show member pathways
 13.61 PIK3CA NOTCH1 KRT7 KRT14 KRAS KIT
6
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.56 TP53 PTEN PIK3CA KRAS KIT HRAS
7
Akt Signaling 63
Show member pathways
 13.54 TP53 PTEN KRAS KIT JAK3 HRAS
8
Cytokine Signaling in Immune system 65
Show member pathways
 13.48 TP53 PIK3CA KRAS KIT JAK3 HRAS
9
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.44 TP53 SERPINA3 PIK3CA MYB KRAS JAK3
10
PAK Pathway 63
Show member pathways
 13.4 PTEN NOTCH1 KRAS KIT HRAS ERBB2
11
IL-2 Pathway 63
Show member pathways
 13.34 TP53 PTEN KRAS JAK3 HRAS ERBB2
12
GAB1 signalosome 65
Show member pathways
 13.21 TP53 PTEN PIK3CA KIT ERBB2 AKT1
13
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.18 TP53 PIK3CA KRAS JAK3 HRAS CYLD
14
Phospholipase-C Pathway 63
Show member pathways
 13.17 TP53 PTEN KRAS KIT HRAS AKT1
15
Human cytomegalovirus infection 36
Show member pathways
 13.05 TP53 PIK3CA KRAS HRAS CCND1 AKT1
16
Focal Adhesion 36 1
Show member pathways
 13.04 PTEN PIK3CA KRAS HRAS ERBB2 CCND1
17
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.02 PTEN PIK3CA KRAS HRAS ERBB2 AKT1
18
CCR5 Pathway in Macrophages 63
Show member pathways
 13 PIK3CA KRAS JAK3 HRAS CCND1 AKT1
19
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13 PTEN PIK3CA KRAS JAK3 HRAS ERBB2
20
Development Angiotensin activation of ERK 22
Show member pathways
 12.94 PIK3CA KRAS KIT HRAS AKT1
21
Endometrial cancer 36
Show member pathways
 12.94 TP53 PTEN PIK3CA KRAS KIT HRAS
22
Measles 36
Show member pathways
 12.9 TP53 PIK3CA JAK3 CCND1 AKT1
23
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.9 PTEN PIK3CA KRAS JAK3 HRAS CCND1
24
MAPK signaling pathway 36 1
12.89 TP53 KRAS KIT HRAS ERBB2 AKT1
25
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.85 TP53 PTEN PIK3CA KRAS KIT HRAS
26
Development HGF signaling pathway 22
Show member pathways
 12.84 TP53 PTEN PIK3CA KRAS HRAS ERBB2
27
Ras signaling pathway 36
Show member pathways
 12.83 PIK3CA KRAS KIT HRAS AKT1
28
Apoptosis Modulation and Signaling 1
Show member pathways
 12.81 TP53 PIK3CA KRAS HRAS AKT1
29
Pathways in cancer 36
12.79 TP53 PTEN PIK3CA NOTCH1 KRAS KIT
30
Relaxin signaling pathway 36
Show member pathways
 12.78 PIK3CA KRT14 KRAS HRAS AKT1
31
4-1BB Pathway 63
Show member pathways
 12.77 TP53 KRAS JAK3 HRAS AKT1
32
Gastric cancer 36
Show member pathways
 12.77 TP53 PTEN PIK3CA NOTCH1 KRAS KIT
33
PI3K-Akt signaling pathway 36
Show member pathways
 12.77 TP53 PTEN PIK3CA NOTCH1 MYB KRAS
34
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.76 PIK3CA KRAS HRAS CCND1 AKT1
35
Immune response IL-23 signaling pathway 22
Show member pathways
 12.73 TP53 PIK3CA KRAS HRAS ERBB2 AKT1
36
T cell receptor signaling pathway 36
Show member pathways
 12.72 PTEN PIK3CA KRAS HRAS AKT1
37
ErbB signaling pathway 36 1
Show member pathways
 12.71 TP53 PTEN PIK3CA KRAS HRAS ERBB2
38
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.7 PTEN PIK3CA KRAS HRAS AKT1
39
Glioma 36
Show member pathways
 12.66 TP53 PTEN PIK3CA NOTCH1 KRAS JAK3
40
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.65 TP53 PTEN PIK3CA KRAS HRAS ERBB2
41
VEGF Signaling 66
Show member pathways
 12.64 TP53 PTEN PIK3CA KRAS HRAS AKT1
42
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.62 TP53 PIK3CA HRAS CCND1 AKT1
43
Prolactin Signaling Pathway 36 1
Show member pathways
 12.61 PTEN PIK3CA KRAS HRAS ERBB2 CCND1
44
JAK-STAT signaling pathway 36
Show member pathways
 12.6 PIK3CA KRAS JAK3 HRAS CCND1 AKT1
45
MicroRNAs in cancer 36
12.6 TP53 PTEN PIK3CA NOTCH1 KRAS HRAS
46
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.58 PTEN PIK3CA KRAS HRAS AKT1
47
Apoptosis Pathway 70
Show member pathways
 12.58 TP53 PIK3CA KRAS HRAS ERBB2 AKT1
48
B cell receptor signaling pathway (KEGG) 36
Show member pathways
 12.54 PTEN PIK3CA KRAS HRAS AKT1
49
Phospholipase D signaling pathway 36
Show member pathways
 12.54 PIK3CA KRAS KIT HRAS AKT1
50
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.53 PIK3CA KRAS JAK3 HRAS AKT1
Sources

GO Terms for Adenoid Cystic Carcinoma

About this section

Cellular components related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 TP53 PTEN PIK3CA NOTCH1 KRT7 KRT14
2 cytosol GO:0005829 9.5 TP53 PTEN PIK3CA NOTCH1 MYB KRT7

Biological processes related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TP53 NOTCH1 NFIB MYBL1 MYB HRAS
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.1 TP53 NOTCH1 NFIB MYB CCND1 BCOR
3 positive regulation of transcription, DNA-templated GO:0045893 10.02 TP53 NOTCH1 NFIB MYBL1 MYB AKT1
4 protein phosphorylation GO:0006468 10.01 PIK3CA KIT JAK3 ERBB2 CCND1 AKT1
5 negative regulation of cell proliferation GO:0008285 10 TP53 PTEN NOTCH1 NFIB HRAS
6 MAPK cascade GO:0000165 9.88 KRAS KIT JAK3 HRAS ERBB2
7 heart development GO:0007507 9.85 TP53 PTEN NOTCH1 ERBB2 BCOR
8 positive regulation of protein phosphorylation GO:0001934 9.83 KRAS HRAS ERBB2 CCND1 AKT1
9 Ras protein signal transduction GO:0007265 9.78 TP53 KRAS HRAS
10 positive regulation of cell proliferation GO:0008284 9.76 PTEN NOTCH1 KRAS KIT HRAS ERBB2
11 positive regulation of epithelial cell proliferation GO:0050679 9.71 NOTCH1 HRAS ERBB2 CCND1
12 protein kinase B signaling GO:0043491 9.69 PTEN PIK3CA AKT1
13 positive regulation of MAP kinase activity GO:0043406 9.67 KRAS KIT HRAS ERBB2
14 liver development GO:0001889 9.65 PIK3CA NOTCH1 KRAS HRAS CCND1
15 anoikis GO:0043276 9.63 PIK3CA AKT1
16 somatic stem cell division GO:0048103 9.62 NOTCH1 KIT
17 phosphatidylinositol 3-kinase signaling GO:0014065 9.62 PTEN PIK3CA ERBB2 AKT1
18 negative regulation of cell size GO:0045792 9.61 PTEN AKT1
19 mitotic G1 DNA damage checkpoint GO:0031571 9.58 TP53 CCND1
20 enzyme linked receptor protein signaling pathway GO:0007167 9.58 JAK3 ERBB2
21 response to isolation stress GO:0035900 9.57 KRAS HRAS
22 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 TP53 NOTCH1
23 positive regulation of gene expression GO:0010628 9.56 TP53 PTEN NOTCH1 KRAS KIT HRAS
24 cellular response to decreased oxygen levels GO:0036294 9.52 PTEN AKT1
25 response to UV-A GO:0070141 9.49 CCND1 AKT1
26 cytokine-mediated signaling pathway GO:0019221 9.17 TP53 PIK3CA KRAS KIT JAK3 CCND1

Molecular functions related to Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.65 TP53 PTEN CYLD CCND1 AKT1
2 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.55 TP53 NOTCH1 NFIB MYBL1 MYB
3 kinase activity GO:0016301 9.43 PIK3CA KIT JAK3 ERBB2 CCND1 AKT1
4 enzyme binding GO:0019899 9.02 TP53 PTEN NOTCH1 CCND1 AKT1
Sources

Sources for Adenoid Cystic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....